Back to Results

Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker ELDN. The company focuses on immunology-based research and development, with an emphasis on therapies that act on the CD40L pathway. Its development programs include tegoprubart, an antibody candidate being studied for applications in organ transplantation, transplant rejection, and amyotrophic lateral sclerosis (ALS). Eledon is also pursuing work related to kidney allograft rejection and xenotransplantation. The company has collaboration agreements with eGenesis, Inc. and NewcelX Ltd., including development activity for NCEL-101 in Type 1 diabetes. Eledon Pharmaceuticals is headquartered in Irvine, California, and was previously known as Novus Therapeutics, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ELDN
$2.06
-28.7% Downside
Overvalued
$9
211.4% Upside
Bargain
Fair
0.0%
November 18, 2026
3.3x
235.1 M
146.8 M
0.2%
91.8%
-6.6
74.9%
Valuation • Fair Value

Eledon Pharmaceuticals Inc (NASDAQ-ELDN) Fair Value by Valuation Model

Review the available estimates for Eledon Pharmaceuticals Inc (NASDAQ-ELDN), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.06

Estimated downside of 28.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.06

Comparable-company valuation reference.

Analyst Price Target

$9

Analysts imply upside of 211.4%.

How to read these valuation models

Use the 4 available valuation references for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Eledon Pharmaceuticals Inc (NASDAQ-ELDN)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

591.2 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Eledon Pharmaceuticals Inc (NASDAQ-ELDN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Eledon Pharmaceuticals Inc (NASDAQ-ELDN)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-6.6

Lower score that deserves closer risk review.

FCF / Net Income

74.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Eledon Pharmaceuticals Inc (NASDAQ-ELDN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Eledon Pharmaceuticals Inc (NASDAQ-ELDN)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 18, 2026

Days to Earnings

57

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Eledon Pharmaceuticals Inc (NASDAQ-ELDN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Eledon Pharmaceuticals Inc (NASDAQ-ELDN) Stock Forecast & Technical Outlook

Review Eledon Pharmaceuticals Inc (NASDAQ-ELDN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Eledon Pharmaceuticals Inc (NASDAQ-ELDN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Eledon Pharmaceuticals Inc (NASDAQ-ELDN) has a Strong Buy consensus, with 6 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 6
Hold 0
Sell 0
FAQ • Fast Investor Answers

Eledon Pharmaceuticals Inc (NASDAQ-ELDN) Stock FAQ

Data-supported answers about Eledon Pharmaceuticals Inc (NASDAQ-ELDN), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.06
Estimated downside 28.7%
Valuation Rating
Overvalued
Estimated downside of 28.7%
Analyst Target
$9
Implied upside 211.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is $2.06. This implies an estimated downside of 28.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 28.7% versus the current market price.

The available analyst price target for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is $9. The analyst target implies estimated upside of 211.4%.

The current financial health read for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is November 18, 2026.

The latest available data indicates no current dividend yield for Eledon Pharmaceuticals Inc (NASDAQ-ELDN).

The current market capitalization listed for Eledon Pharmaceuticals Inc is 235.1 M.

The current enterprise value listed for Eledon Pharmaceuticals Inc is 146.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Eledon Pharmaceuticals Inc is NASDAQ-ELDN, and the stock is listed on NASDAQ.

Eledon Pharmaceuticals Inc (NASDAQ-ELDN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Eledon Pharmaceuticals Inc is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Eledon Pharmaceuticals Inc is 91.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B